Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System - PubMed (original) (raw)
Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System
Derrick J Stobaugh et al. J Am Acad Dermatol. 2013 Sep.
Abstract
Background: Some studies have purported to link isotretinoin prescribed for acne with the development of inflammatory bowel disease (IBD).
Objective: We sought to identify existence of disproportionate attorney-initiated reporting of isotretinoin-associated IBD in the Food and Drug Administration Adverse Event Reporting System (FAERS).
Methods: A total of 3,338,835 cases (2003-2011) were downloaded from the FAERS. These were queried for IBD cases reported with isotretinoin for a usage indication of acne while recording reporter category. Trends were analyzed over time for reports by attorneys for all medications compared with reports of IBD with isotretinoin. Signal inflation factor was calculated to determine the distortion of pharmacovigilance signals for IBD with isotretinoin.
Results: There were 2214 cases of IBD resulting from isotretinoin. Attorneys reported 1944 (87.8%) cases whereas physicians reported 132 (6.0%) and consumers reported 112 (5.1%) cases (P value < .01). For the entire FAERS, only 87,905 of the total 2,451,314 (3.6%) reports for all drug reactions during the same time period were reported by attorneys (P value < .01). The signal inflation factor for IBD with isotretinoin for attorney-initiated reports was 5.82, signifying a clear distortion.
Limitations: The accuracy of reports was not ascertained.
Conclusions: Attorney-initiated reports inflate the pharmacovigilance signal of isotretinoin-associated IBD in the FAERS.
Keywords: FAERS; FDA; Food and Drug Administration; Food and Drug Administration Adverse Event Reporting System; IBD; VAERS; Vaccine Adverse Event Reporting System; acne vulgaris; acne vulgaris/drug therapy; dermatologic agents/adverse effects; inflammatory bowel disease; inflammatory bowel diseases; inflammatory bowel diseases/chemically induced; isotretinoin; postmarketing; product surveillance.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Similar articles
- Possible association between isotretinoin and inflammatory bowel disease.
Reddy D, Siegel CA, Sands BE, Kane S. Reddy D, et al. Am J Gastroenterol. 2006 Jul;101(7):1569-73. doi: 10.1111/j.1572-0241.2006.00632.x. Am J Gastroenterol. 2006. PMID: 16863562 - Concomitant antibiotic usage does not augment the risk of inflammatory bowel disease with isotretinoin treatment for acne: a review of the Food and Drug Administration Adverse Event Reporting System.
Stobaugh DJ, Deepak P, Ehrenpreis ED. Stobaugh DJ, et al. Eur J Clin Pharmacol. 2013 Apr;69(4):1041-2. doi: 10.1007/s00228-012-1416-1. Epub 2012 Oct 6. Eur J Clin Pharmacol. 2013. PMID: 23052415 Review. No abstract available. - Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System.
Deepak P, Stobaugh DJ, Sherid M, Sifuentes H, Ehrenpreis ED. Deepak P, et al. Aliment Pharmacol Ther. 2013 Aug;38(4):388-96. doi: 10.1111/apt.12385. Epub 2013 Jun 26. Aliment Pharmacol Ther. 2013. PMID: 23802849 - Managing nonteratogenic adverse reactions to isotretinoin treatment for acne vulgaris.
Reilly BK, Ritsema TS. Reilly BK, et al. JAAPA. 2015 Jul;28(7):34-9. doi: 10.1097/01.JAA.0000459815.24908.02. JAAPA. 2015. PMID: 26107793 Review.
Cited by
- Association of anxiolytic drugs with Torsade de Pointes: a pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System.
Ali Z, Ismail M, Rehman IU, Goh KW, Razi P, Ming LC. Ali Z, et al. J Pharm Policy Pract. 2024 Sep 16;17(1):2399716. doi: 10.1080/20523211.2024.2399716. eCollection 2024. J Pharm Policy Pract. 2024. PMID: 39291052 Free PMC article. - Anti-Fibrotic Potential of All Trans Retinoic Acid in Inflammatory Bowel Disease.
Auci DL, Egilmez NK, Dryden GW. Auci DL, et al. J Gastroenterol Pancreatol Liver Disord. 2018;6(3):10.15226/2374-815X/6/3/001126. doi: 10.15226/2374-815X/6/3/001126. Epub 2018 May 28. J Gastroenterol Pancreatol Liver Disord. 2018. PMID: 30740522 Free PMC article. No abstract available. - Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.
Rogers JR, Sarpatwari A, Desai RJ, Bohn JM, Khan NF, Kesselheim AS, Fischer MA, Gagne JJ, Connolly JG. Rogers JR, et al. Drug Saf. 2019 Jan;42(1):85-93. doi: 10.1007/s40264-018-0703-x. Drug Saf. 2019. PMID: 30066315 - Research Techniques Made Simple: Pharmacoepidemiology Research Methods in Dermatology.
Noe MH, Gelfand JM. Noe MH, et al. J Invest Dermatol. 2018 Feb;138(2):e13-e18. doi: 10.1016/j.jid.2017.10.026. J Invest Dermatol. 2018. PMID: 29389330 Free PMC article. - Algorithm for acne treatment: Ibero-Latin American consensus.
Bagatin E, Florez-White M, Arias-Gomez MI, Kaminsky A. Bagatin E, et al. An Bras Dermatol. 2017 Sep-Oct;92(5):689-693. doi: 10.1590/abd1806-4841.20177003. An Bras Dermatol. 2017. PMID: 29166508 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources